Compare · COCH vs EW
COCH vs EW
Side-by-side comparison of Envoy Medical Inc. (COCH) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COCH and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $52.38B, about 908.3x COCH ($57.7M).
- COCH has been more active in the news (4 items in the past 4 weeks vs 3 for EW).
- EW has more recent analyst coverage (25 ratings vs 2 for COCH).
- Company
- Envoy Medical Inc.
- Edwards Lifesciences Corporation
- Price
- -
- -
- Market cap
- $57.7M
- $52.38B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 4
- 3
- Recent ratings
- 2
- 25
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest COCH
- SEC Form PRE 14A filed by Envoy Medical Inc.
- Envoy Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- SEC Form 10-Q filed by Envoy Medical Inc.
- Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones
- Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial
- Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
- Envoy Medical Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device
- Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
- Envoy Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest EW
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,967 worth of shares (619 units at $92.03) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Edwards Lifesciences Corporation
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- CVP, JAPAC Markowitz Wayne sold $12,588 worth of shares (146 units at $86.03), decreasing direct ownership by 0.67% to 21,534 units (SEC Form 4)
- CVP, JAPAC Markowitz Wayne exercised 9,628 shares at a strike of $74.02 and sold $818,958 worth of shares (9,628 units at $85.06) (SEC Form 4)
- UBS initiated coverage on Edwards Lifesciences with a new price target
- CEO Zovighian Bernard J gifted 320 shares, received a gift of 320 shares and sold $245,134 worth of shares (2,921 units at $83.93), decreasing direct ownership by 0.32% to 98,845 units (SEC Form 4)
- Edwards Lifesciences upgraded by Leerink Partners with a new price target
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Second Quarter Results